<DOC>
	<DOCNO>NCT01078870</DOCNO>
	<brief_summary>The project double-blind , randomize , placebo control clinical trial compare 3 group schizophrenic subject , less moderate degree negative symptom carry homozygous risk genotype ( TT ) NRG1-P3 , group 30 individual , treat add-on escitalopram 10-20 mg/day , duloxetine 30-60 mg/day , placebo . The treatment duration 8 week . The investigator evaluate Positive Negative Symptom Scale ( PANSS ) baseline , Day 14 , Day 28 , Day 42 , Day 56 . The primary outcome interest difference average reduction negative symptom score among 3 group average decrease 2 negative symptom indicate improvement .</brief_summary>
	<brief_title>Trial Antidepressant Treatment Negative Symptom Schizophrenia With NRG1 Risk Genotype</brief_title>
	<detailed_description>Negative symptom schizophrenia endure detrimental . The underlying pathophysiology negative symptom yet understood . Previous clinical trial antidepressant add-on therapy negative symptom schizophrenia patient usually find merely trend favor augmentation strategy . Since schizophrenia heterogeneous disorder , clinical study often unable reveal conclusive result . Thus effort make classify relatively homogeneous group patient different approach . Here , propose translational study originate novel result animal study genetic study describe follows.We study neurobiological difference mice heterozygous deletion NRG1 ( NRG1+/-mice ) comparison wild-type littermates . It find antidepressant effect desipramine immobilization markedly increase NRG1+/-mice assess two model , force swim test tail suspension test . Furthermore , expression serotonin transporter ( SERT ) up-regulated brain region NRG1+/-mice , indicate basal activity serotonin reduce high uptake rate NRG1+/-mice . Our data indicate serotonin hypo-function may involve immobilization symptom schizophrenia NRG1 defect . Increased immobility force swim test mouse suggest animal model negative symptom . Thus study imply serotonin transporter blocker may beneficial treatment negative symptom subtypes schizophrenia , especially patient NRG1 defect , could test examine specific polymorphism NRG1 gene.We identify novel promoter variant ( TC ) , name NRG1-P3 , locate promoter region type V NRG1 , direct sequencing study Taiwanese schizophrenic patient find significantly associate schizophrenia large case-control sample . Through luciferase reporter assay , find promoter construct risk genetic variant ( T allele ) NRG1-P3 significant low luciferase reporter activity protect allele ( C allele ) . It imply schizophrenic patient T allele NRG1-P3 might lower NRG1 expression C allele . It hypothesize negative symptom schizophrenic patient T allele NRG1-P3 responsive SSRI SNRI treatment.The project double-blind , randomize , placebo control clinical trial compare 3 group schizophrenic subject , less moderate degree negative symptom carry homozygous risk genotype ( TT ) NRG1-P3 , group 30 individual , treat add-on escitalopram 10-20 mg/day , duloxetine 30-60 mg/day , placebo . The treatment duration 8 week . We evaluate Positive Negative Symptom Scale ( PANSS ) baseline , Day 14 , Day 28 , Day 42 , Day 56 . The primary outcome interest difference average reduction negative symptom score among 3 group average decrease 2 negative symptom indicate improvement.The project novel feasible ( 1 ) first clinical trial treatment negative symptom accord different genotype patient help fulfill prospect individualized medication . ( 2 ) research finding translational study base upon novel unique come research team . ( 3 ) research team master clinical study many clinical resource recruit enough patient .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1. aged 1865 2. meet diagnostic criterion Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) schizophrenia 3. genotype NRG1P3 homozygous risk genotype ( TT ) 4. secondgeneration antipsychotic treatment relatively stable clinical status ( change prescribe medication past 8 week symptom item positive subscale PANSS score 4 ) 5. moderate mark negative symptom ( score 4 6 item N2 , emotional withdrawal , N4 , passivity/apathetic social withdrawal ) 1. lifetime diagnosis schizoaffective disorder , bipolar affective disorder , major depressive disorder score Hamilton Depression Rating Scale ( HAMD ) 18 2. genotype NRG1P3 TC CC 3. major systemic illness 4. receive firstgeneration antipsychotic already antidepressant moodstabilizing agent adjuvant 5. substance abuse past 6 month 6. pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Negative symptom</keyword>
</DOC>